Drug News

Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR

DelveInsight’s recent Market Insights report on Metastatic HER2-Positive Breast Cancer provides a comprehensive analysis of current treatment practices, emerging drugs, market share of individual therapies, and the anticipated market size from 2019 to 2032 across the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Insights from the Report:

1.        Incident Population and Growth: The total incident population of HER2-positive breast cancer in the seven major markets was nearly 100,000 cases in 2022. DelveInsight’s analysis indicates an expected increase in cases during the forecast period from 2023 to 2032.

2.        Leading Companies and Drug Development: Major players in the metastatic HER2-positive breast cancer space, including Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, and Pfizer, are actively developing novel drugs expected to enter the market in the coming years.

3.        Pipeline Therapies: The report highlights promising therapies in the pipeline, such as SYD985 (trastuzumab duocarmazine), Giredestrant, ARX788, Zanidatamab, and IBRANCE (palbociclib).

4.        Market Dynamics: The market dynamics are influenced by factors like patent expiries, biosimilars, and advancements in treatment landscapes. The report emphasizes the transformative impact of targeted therapies like trastuzumab (Herceptin), pertuzumab (Perjeta), and ado-trastuzumab emtansine (Kadcyla).

5.        Treatment Landscape: The treatment landscape includes a variety of modalities, such as targeted therapy and hormonal therapy. HERCEPTIN and PERJETA have been standard-of-care options, but recent launches like ENHERTU have brought notable shifts in patient preferences.

6.        Expected Market Growth: The metastatic HER2-positive breast cancer treatment market is anticipated to experience gradual growth, driven by the presence of established blockbuster HER2-targeting therapies and promising therapies in development.

7.        Market Challenges: Challenges include the complexity of the disease, development of resistance to existing therapies, high treatment costs impacting accessibility, and limitations in comprehensive molecular profiling.

Market Report Metrics:

•          Study Period: 2019–2032

•          Coverage: 7MM [the United States, the EU4, and Japan]

•          Market Size in 2022: USD 2.6 Billion

•          Key Companies: Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others

•          Key Pipeline Therapies: SYD985, Giredestrant, ARX788, Zanidatamab, IBRANCE, and others

Scope of the Report:

The report covers a thorough assessment of current and emerging therapies, market dynamics, competitive intelligence, unmet needs, key opinion leaders’ views, analyst perspectives, and market access and reimbursement insights.

For further details and in-depth insights, readers are encouraged to access the complete Metastatic HER2-Positive Breast Cancer Market Insights report by DelveInsight.

Source: PR Newswire


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker